CEDAR KNOLLS, N.J.,
Nov. 8, 2017 /PRNewswire/
-- MYOS RENS Technology Inc. ("MYOS" or "the Company")
(NASDAQ: MYOS), a bionutrition company and owner of
Fortetropin®, the natural food product that helps build
lean muscle, today announced the debut of its collegiate sports
marketing platform promoting the benefits of muscle health.
Through a sponsorship deal with IMG College, a division of IMG,
MYOS will market its products to a key demographic– collegiate
athletic programs and their fans.
"IMG College has a large national footprint across collegiate
athletics that can open the way for us to reach not only the
athletic departments but also the faculty and alumni," said
Joseph Mannello, Chief Executive
Officer of MYOS. "Sports nutrition is a significant focus of MYOS
and we are proud to offer an all-natural nutrition product that has
been clinically shown to help the body build lean muscle. There has
never been a greater commitment towards health and nutrition on
college campuses and in athletics as there is today. Our
products are BSCG-certified drug free and WADA-compliant, and are
ideal for sports programs."
"We are thrilled that MYOS has chosen to invest in the college
space which continues to deliver a vibrant, passionate and loyal
audience," said Tim Pernetti,
President, IMG College. "We know that MYOS recognizes the
tremendous value in collegiate athletics and we look forward to
working with them in this innovative partnership."
MYOS is building a solid foundation for future advancements into
key audiences through college sports, giving them a platform to
potentially take Fortetropin® into additional sports markets,
including various professional programs.
IMG College represents more than 200 colleges across multimedia
rights, licensing and sponsorships. In addition, through
relationships with major universities, conferences, and events, it
provides leading brands with multi-channel platforms to connect
with college sports fans at the national, regional, and local
levels.
About MYOS RENS Technology Inc.
MYOS RENS Technology (MYOS), "The Muscle Company™", is a
Cedar Knolls, NJ-based
bionutrition company that develops and markets products that
improve muscle health and performance. MYOS is the owner of
Fortetropin®, the world's first clinically-demonstrated myostatin
reducer. Myostatin is a natural regulatory protein, which inhibits
muscle growth. Fortetropin® is a fertilized egg yolk based product
manufactured via a proprietary process to retain and optimize its
biological activity. Fortetropin® has been clinically shown to
increase muscle size and lean body mass in conjunction with
resistance training. MYOS believes Fortetropin® has the potential
to redefine existing standards of physical health and wellness. For
more information, please visit www.MYOSRENS.com
Forward-Looking Statements
Any statements in this release that are not historical facts are
forward-looking statements. Actual results may differ materially
from those projected or implied in any forward-looking statements.
Such statements involve risks and uncertainties, including but not
limited to those relating to product and customer demand, market
acceptance of our products, the ability to create new products
through research and development, the successful results of
strategic initiatives, the successful launch of our products,
including Qurr® products, the success of our research and
development, the results of the clinical evaluation of
Fortetropin® and its effects, the ability to enter
into partnership opportunities, the ability to generate the
forecasted revenue stream and cash flow from sales of our products,
the ability to achieve a sustainable, profitable business, the
effect of economic conditions, the ability to protect our
intellectual property rights, competition from other providers and
products, the continued listing of our securities on the Nasdaq
Stock Market, risks in product development, our ability to raise
capital to fund continuing operations, and other factors discussed
from time to time in the Company's Securities and Exchange
Commission filings. The Company undertakes no obligation to update
or revise any forward-looking statement for events or circumstances
after the date on which such statement is made except as required
by law.
These statements have not been evaluated by the Food and Drug
Administration. Our products are not intended to diagnose, treat,
cure or prevent any disease.
Investor Relations:
Porter LeVay & Rose
Michael Porter, President
Phone: 212-564-4700
Email: MYOS@plrinvest.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/myos-rens-technology-inc-launches-collegiate-sports-marketing-platform-300551438.html
SOURCE MYOS RENS Technology